Compare MHF & KRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MHF | KRMD |
|---|---|---|
| Founded | 1988 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.1M | 186.3M |
| IPO Year | N/A | N/A |
| Metric | MHF | KRMD |
|---|---|---|
| Price | $6.95 | $5.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.13 |
| AVG Volume (30 Days) | 57.2K | ★ 201.0K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 4.29% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $39,070,637.00 |
| Revenue This Year | N/A | $23.36 |
| Revenue Next Year | N/A | $18.63 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 22.12 |
| 52 Week Low | $5.92 | $1.86 |
| 52 Week High | $6.79 | $6.11 |
| Indicator | MHF | KRMD |
|---|---|---|
| Relative Strength Index (RSI) | 44.95 | 64.27 |
| Support Level | $6.88 | $5.44 |
| Resistance Level | $6.98 | $5.88 |
| Average True Range (ATR) | 0.08 | 0.35 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 20.60 | 76.25 |
Western Asset Municipal High Income Fund Inc is a diversified closed-end management investment company. The company's objective is to seek high current income exempt from federal income taxes. It invests predominantly in intermediate and long-term municipal debt securities issued by state and local governments.
KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on mechanical infusion products, the FREEDOM Infusion Systems. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).